A5052133567- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Hematopoietic Stem Cell Transplantation
- Chronic Lymphocytic Leukemia Research
- Blood disorders and treatments
- Chronic Myeloid Leukemia Treatments
- Biomedical Ethics and Regulation
- Pluripotent Stem Cells Research
- Lung Cancer Research Studies
- Immune Cell Function and Interaction
- Eosinophilic Disorders and Syndromes
- Polyomavirus and related diseases
- Respiratory viral infections research
- Neutropenia and Cancer Infections
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- Single-cell and spatial transcriptomics
- Takotsubo Cardiomyopathy and Associated Phenomena
- Protein Degradation and Inhibitors
- CAR-T cell therapy research
- Health Systems, Economic Evaluations, Quality of Life
- Bone and Joint Diseases
- T-cell and Retrovirus Studies
McMaster University
2022-2025
Hamilton Health Sciences
2022-2024
Juravinski Hospital
2024
Leukemia & Lymphoma Society of Canada
2024
Juravinski Cancer Centre
2022-2023
Princess Margaret Cancer Centre
2020-2022
University Health Network
2020-2022
University of Toronto
2020-2022
London Health Sciences Centre
2018-2019
National Commission for the Knowledge and Use of Biodiversity
2018
The aim of this study was to evaluate real-world clinical outcomes and transplant-related complications allogeneic stem cell transplantation (alloSCT) for Hodgkin lymphoma (HL). This a single-centre, retrospective analysis relapsed refractory (R/R) HL patients who received an alloSCT between 1 January 2016 29 February 2024 in Hamilton, Ontario. primary endpoint overall survival (OS). secondary endpoints were progression-free (PFS), non-relapse mortality (NRM), graft-versus-host...
Cancer patients have a higher risk of severe sepsis in comparison with non-cancer patients, an increased for hospital-acquired infections (HAI), particularly multidrug resistant bacteria (MDRB). The aim the study is to describe frequency and characteristics HAI MDRB critically ill cancer patients. We conducted 18-month prospective admitted ≥48 h ICU at referral center Mexico. Patients hematological malignancies (HM) were compared solid tumors. Demographic clinical data recorded. Mortality...
The burden of influenza infections in patients with hematological malignancies (HMs) is not well defined. We describe the clinical presentation and associated outcomes at two comprehensive cancer centers (center 1 United States center 2 Mexico). Clinical laboratory data on HMs infection diagnosed from April 2009 to May 2014 were reviewed retrospectively. A total 190 included, majority male (63%) a median age 49 years (range, 1-88 years), had active or refractory (76%). Compared 1,...
Despite most acute myeloid leukemia (AML) patients entering remission following chemotherapy, outcomes remain poor due to surviving leukemic cells that contribute relapse. The nature of these enduring is poorly understood. Here, through temporal single-cell transcriptomic characterization AML hierarchical regeneration in response we reveal a cell population: enriched (RECs). RECs are defined by CD74/CD68 expression, and although derived from stem (LSCs), devoid stem/progenitor capacity....
On behalf of Cell Therapy Transplant Canada (CTTC), we are pleased to present the Abstracts CTTC 2023 Annual Conference. The conference was held in-person, 31 May–2 June 2023, in Halifax, Nova Scotia at Westin Scotian hotel. Poster authors presented their work during a lively and engaging welcome reception on Thursday, 1 June, oral abstract were featured session afternoon Friday, 2 2023. Twenty-three (23) abstracts selected for presentation as posters four (4) presentations. submitted within...